FDA OKs subcutaneous version of J&J's Darzalex

May 01, 2020 2:41 PM ETJohnson & Johnson (JNJ), HALO, GMABJNJ, HALO, GMABBy: Douglas W. House, SA News Editor2 Comments
  • The FDA approves a subcutaneous formulation of Johnson & Johnson's (JNJ -1.9%) multiple myeloma med Darzalex (daratumumab). Originally, the CD38-directed cytolytic antibody was administered via intravenous infusion.
  • The formulation is based on Halozyme's (HALO +0.6%) Enhanze drug delivery technology.
  • J&J in-licensed exclusive global rights to the product from Genmab A/S (GMAB +2.6%) in August 2012.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.